| Vol. 15.03 – 30 January, 2024 |
| |
|
|
| In this prospective observational study, 1,171 patients with PDAC who underwent pancreatectomy were enrolled and extensively followed-up. Proteomic profiling of 191 patient samples unveiled clinically relevant functional protein modules. [Nature Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers demonstrated the use of cell type-specific DNA methylation markers for determining the fraction of specific cell types in human islet and pancreas specimens. [Diabetes] |
|
|
|
| Investigators explored changes in biomarkers of beta-cell function and insulin sensitivity and efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide. [Journal Of Clinical Endocrinology & Metabolism] |
|
|
|
| Researchers examined pH regulation of the Golgi and identified a partial alkalinization of the Golgi lumen in a diabetes model. They generated a β-cell-specific knockout of the v0a2 subunit of the v-ATPase pump, which anchors the v-ATPase to the Golgi membrane. [American Journal Of Physiology-Endocrinology And Metabolism] |
|
|
|
| Since OATP2B1 is present in beta cells of the human pancreas, scientists investigated if OATP2B1 facilitated the local accumulation of statins in a rat beta-cell model INS-1 832/13 thereby amplifying statin-induced toxicity. [Toxicology Mechanisms And Methods] |
| |
|
|
| Investigators identified a disintegrin and metalloproteinase domain (ADAM) 9 as a modulator of PDAC progression via stabilization of wild-type and mutant KRAS proteins. [Nature Cancer] |
|
|
|
| Researchers clarified the expression of high-temperature requirement protein A1 (HTRA1) in PDAC using bioinformatics and immunohistochemistry of tissue chip, and found that HTRA1 was significantly upregulated in PDAC. [Cell Death Discovery] |
|
|
|
| Investigators developed a stemness-based and ferroptosis-related prognostic model, which could help predict overall survival for PDAC patients. Targeting ferroptosis may be a promising therapeutic strategy to inhibit PDAC progression by suppressing cancer stem cells. [Translational Oncology] |
|
|
|
| Scientists evaluated the gene and protein expression differences in two myofibroblastic cancer-associated fibroblast (CAF) lines using single-cell and bulk RNA-sequencing. They utilized proliferation and migration assays to determine the effect of different CAF lines on a tumor cell line. [Journal Of Surgical Oncology] |
|
|
|
|
| The authors discuss the mechanisms of cellular plasticity involving cellular adaptation and tumor microenvironment and provided a comprehensive understanding of its role in therapy resistance and ways to overcome it. [Cancer And Metastasis Reviews] |
|
|
|
| Scientists identify the limitations that have to be overcome before stem cell therapy for diabetes becomes reliable and reproducible. As an alternative to cell therapy, the use of stem cell-derived extracellular vesicles is discussed as a future possibility. [Stem Cell Research & Therapy] |
|
|
|
|
| FibroGen, Inc. announced the graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s Precision PromiseSM Phase II/III adaptive platform trial, which evaluated pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with mPDAC. [FibroGen, Inc.] |
|
|
|
|
| February 22 – 24, 2024 Austin, Texas, United States |
|
|
|
|
|
| University of Galway – Galway, Ireland, United Kingdom |
|
|
|
| Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| Columbia University Irving Medical Center – New York, New York, United States |
|
|
|
| Novo Nordisk – Beijing, China |
|
|
|
| University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
|